Biological Availability
Conditions
Keywords
Relative bioavailability, Rivaroxaban
Brief summary
Rivaroxaban is a substance developed for use in the treatment of blood coagulation disorders. Thrombosis (blood clots) can occur as a result of excessive coagulation activity in the blood vessels. Excessive coagulation activity can occur in children as well, and rivaroxaban is therefore being developed for the treatment of thromboembolic events in children and adolescents. As small children are often unable to swallow tablets, an oral suspension (mixture of a liquid containing finely distributed solids) has been developed which allows dosing according to body weight. The objective of this trial is to compare the bioavailability (proportion of a substance that remains available unchanged in the blood circulation) of a rivaroxaban oral solution with that of the rivaroxaban tablet approved for treatment. In order to evaluate the potential influence of food, the oral suspension containing 20 mg rivaroxaban will be taken after consuming food. In addition, the pharmacokinetics (concentrations of the drug and breakdown products (metabolites) in blood), safety and tolerability will be assessed.
Interventions
DRUGRivaroxaban (Xarelto, BAY59-7939)
Sponsors
Janssen Research & Development, LLC
Bayer
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male subjects * Age: 18 to 55 years (inclusive) at the first screening examination
Exclusion criteria
* Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal * Known coagulation disorders (eg von Willebrand's disease, hemophilia) * Known disorders with increased bleeding risk (eg periodontosis, hemorrhoids, acute gastritis, peptic ulcer) * Known sensitivity to common causes of bleeding (eg nasal) * Regular use of medicines * Clinically relevant findings in the ECG (electrocardiogram) such as a second- or third-degree AV block, prolongation of the QRS complex over 120 msec or of the QTc-interval over 450 msec * Clinically relevant findings in the physical examination * Clinically relevant deviations of the screened laboratory parameters from reference ranges * Participation in another clinical study during the preceding 3 months (Last Treatment from previous study to First Treatment of new study)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area Under the Concentration Versus Time Curve From Zero to Infinity After a Single Dose (AUC) | 0-72 hours |
| Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose (AUC/D) | 0-72 hours |
| Maximum Observed Drug Concentration in Measured Matrix After a Single Dose (Cmax) | 0-72 hours |
| Maximum Observed Drug Concentration in Measured Matrix Divided by Dose (Cmax/D) | 0-72 hours |
Secondary
| Measure | Time frame |
|---|---|
| Maximum Observed Drug Concentration Divided by Drug Concentration at 24 hours (Cmax/C24h) | 0-72 hours |
| Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose per Kilogram Body Weight (AUC,norm) | 0-72 hours |
| Terminal Half Life (t1/2) | 0-72 hours |
| Time to Reach Maximum Observed Drug Concentration (tmax) | 0-72 hours |
| Area Under the Concentration Versus Time Curve From Zero to Last Quantifiable Concentration [AUC(0tlast)] | 0-72 hours |
| Maximum Observed Drug Concentration Divided by Dose per Kilogram Body Weight (Cmax,norm) | 0-72 hours |
| Mean Residence Time (MRT) | 0-72 hours |
Countries
Germany
Outcome results
None listed